Regorafenib assessment in refractory advanced colorectal cancer: RegARd-C study protocol.

Hendlisz, Alain; Deleporte, Amélie; Vandeputte, Caroline; Charette, Nicolas; Paesmans, Marianne; Guiot, Thomas; Garcia, Camilo; Flamen, Patrick

Hendlisz, Alain; Deleporte, Amélie; Vandeputte, Caroline; Charette, Nicolas; Paesmans, Marianne; Guiot, Thomas; Garcia, Camilo; Flamen, Patrick.

Affiliation

Hendlisz A; Medicine Department, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
Deleporte A; Medicine Department, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
Vandeputte C; Medicine Department, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
Charette N; Medicine Department, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
Paesmans M; Data Centre, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
Guiot T; Nuclear Medicine Department, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
Garcia C; Nuclear Medicine Department, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
Flamen P; Nuclear Medicine Department, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.

BMJ Open ; 5(3): e007189, 2015 Mar 09.

Article in En | MEDLINE | ID: mdl-25753361

Subject(s)
Key words

CHEMOTHERAPY; NUCLEAR MEDICINE

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Phenylurea Compounds / Pyridines / Research Design / Colorectal Neoplasms / Adenocarcinoma / Antineoplastic Agents Type of study: Clinical_trials / Guideline / Observational_studies / Prognostic_studies Aspects: Ethics Limits: Humans Language: En Journal: BMJ Open Year: 2015 Document type: Article Affiliation country: Bélgica Country of publication: Reino Unido

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google